Norman Swan

But there are benefits for boys.

Which is interesting because it really only went to the age of 26 because HPV immunization hasn't gone on for that long.

But it was hundreds of thousands of boys who'd been immunized versus a two million control group.

So it was really what you would call a case control study and showed that even with the small numbers at that age, you still saw a significant effect.

So guess what topic we're going to talk about next.

No one's written in.

We do have a sound.

We do.

It's been normal and determined.

I'm looking through the glass at James, our producer, and he's iffy about it.

I think it's a good sound myself.

And for those of you who wonder what it is, it's the sound of constipation because there are side effects of these GLP-1 drugs.

Anyway, the headlines this week were that Eli Lilly, the manufacturer of Terzepatite, the Monjaro, the drug for obesity but also type 2 diabetes, they seem to have left the negotiating table with the Pharmaceutical Business Advisory Committee saying the price being demanded of them is too low.

And dulaglutide's another one?

The Pharmaceutical Benefits Advisory Committee, though, makes an economic judgment on this as well as other effectiveness judgments and came to the conclusion that for the benefits that they were claiming, the price was too high.

What often happens behind the scenes with the PBAC and getting on the PBS is negotiation, is that they go into negotiation with the company and

That's a very good question, who actually does the negotiation.

I think it's the Pharmaceutical Benefits Advisory Committee that does, but I could be wrong about that.

Point is, there's a negotiation.

And a lot of drug companies like to do what Apple does, for example.